These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22278741)

  • 1. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy.
    Zinellu A; Sotgia S; Loriga G; Deiana L; Satta AE; Carru C
    Amino Acids; 2012 Oct; 43(4):1499-507. PubMed ID: 22278741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.
    Zinellu A; Sotgia S; Pisanu E; Loriga G; Deiana L; Satta AE; Carru C
    Eur J Pharm Sci; 2012 Aug; 47(1):117-23. PubMed ID: 22659373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
    Zinellu A; Sotgia S; Mangoni AA; Sanna M; Satta AE; Carru C
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):153-9. PubMed ID: 25534866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients.
    Zinellu A; Sotgia S; Sotgiu E; Assaretti S; Baralla A; Mangoni AA; Satta AE; Carru C
    Nutr Metab Cardiovasc Dis; 2017 Sep; 27(9):822-829. PubMed ID: 28755807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
    Zinellu A; Sotgia S; Mangoni AA; Sotgiu E; Ena S; Satta AE; Carru C
    J Pharm Biomed Anal; 2016 Sep; 129():383-388. PubMed ID: 27454090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.
    Chang JW; Yang WS; Min WK; Lee SK; Park JS; Kim SB
    Am J Kidney Dis; 2002 Jun; 39(6):1213-7. PubMed ID: 12046033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease.
    Dummer CD; Thome' FS; Zingano B; Lindoso A; Veronese FV
    J Nephrol; 2008; 21(6):900-8. PubMed ID: 19034875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezetimibe/simvastatin.
    Montecucco F; Quercioli A; Mach F
    Expert Opin Drug Saf; 2009 Nov; 8(6):715-25. PubMed ID: 19968571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
    Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
    Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
    Gerdts E; Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber C; Ray S; Skjærpe T; Wachtell K; Willenheimer R
    Am J Cardiol; 2010 Dec; 106(11):1634-9. PubMed ID: 21094366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.